Holles Natalie C. 4

What Happened

• Natalie C. Holles, Chief Executive Officer and President of Aura Biosciences (AURA), was granted a total of 3,323,065 award units on May 19, 2026: 600,118 restricted stock units (RSUs), 553,844 performance RSUs (PRSUs), and 2,169,103 derivative shares (option-type award). All grants were reported as awards (code A) at $0.00 per share (no cash paid; grant value reported as $0).

Key Details

• Transaction date: 2026-05-19; filing date: 2026-05-19 (filed same day).
• Award breakdown: 600,118 RSUs (F1); 553,844 PRSUs (F2); 2,169,103 derivative/option-style award (F3).
• Vesting highlights:
  • RSUs (F1): Vest in four substantially equal annual installments beginning April 15, 2027, subject to continued service.
  • PRSUs (F2): Subject to time-based vesting (four equal annual installments starting April 15, 2027) and a performance condition; expire on the earlier of the 6th anniversary or termination of service if unvested.
  • Derivative/option (F3): 25% of underlying shares vest April 30, 2027; remaining shares vest pro rata in 36 monthly installments thereafter, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• These awards were granted as inducement awards (to induce service), per footnotes.

Context

• These are grants (not open-market purchases or sales). RSUs and PRSUs convert to stock only if vesting conditions are met; PRSUs additionally require achievement of performance goals. The derivative award appears to be option-like with time-based vesting; no immediate sale or cash exercise occurred. Inducement grants are common for new hires or role changes and do not, by themselves, indicate a buy/sell market signal.